Condition
Recurrent Langerhans Cell Histiocytosis
ClinicalTrials.gov condition label
Clinical trials
13 shownQ702 for the Treatment of Patients With Hematologic MalignanciesNCT06712810 · 2025-08-27
RECRUITINGSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNCT04320888 · 2021-05-03
ACTIVE_NOT_RECRUITINGTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNCT04284774 · 2020-10-13
ACTIVE_NOT_RECRUITINGIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)NCT04195555 · 2020-07-20
ACTIVE_NOT_RECRUITINGUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)NCT03698994 · 2018-11-14
ACTIVE_NOT_RECRUITINGPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250 · 2018-08-13
COMPLETEDErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)NCT03210714 · 2018-06-05
ACTIVE_NOT_RECRUITINGEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)NCT03213652 · 2018-04-17
ACTIVE_NOT_RECRUITINGSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)NCT03213678 · 2017-11-28
COMPLETEDTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)NCT03213665 · 2017-11-13
COMPLETEDOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)NCT03233204 · 2017-09-14
COMPLETEDLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)NCT03213704 · 2017-08-23
ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITINGCommon interventions
Computed TomographyPROCEDURE7Magnetic Resonance ImagingPROCEDURE7Biospecimen CollectionPROCEDURE6X-Ray ImagingPROCEDURE6Positron Emission TomographyPROCEDURE5Radionuclide ImagingPROCEDURE5Bone Marrow Aspiration and BiopsyPROCEDURE4Bone ScanPROCEDURE4Laboratory Biomarker AnalysisOTHER4Pharmacological StudyOTHER4EnsartinibDRUG2ErdafitinibDRUG2IvosidenibDRUG2Larotrectinib SulfateDRUG2OlaparibDRUG2PalbociclibDRUG2SamotolisibDRUG2SelpercatinibDRUG2TazemetostatDRUG2TipifarnibDRUG2UlixertinibDRUG2Axl/Mer/CSF1R Inhibitor Q702DRUG1Biopsy ProcedurePROCEDURE1Bone Marrow AspirationPROCEDURE1Bone Marrow BiopsyPROCEDURE1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING8
COMPLETED4
RECRUITING1
Phase mix
PHASE212
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.